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Abstract
Purpose There is lack of consensus on the prognostic value of received high dose intensity in osteosarcoma survivorship. 
Many studies have not shown a clear survival benefit when dose intensity is increased. The aim of this study is to go beyond 
chemotherapy intensification by arm-wide escalation of intended dose and/or compression of treatment schedule, while 
conversely addressing the relationship between treatment intensity and survival at the patient level. The study focusses on 
the difference in outcome results, based on a novel, progressively more individualised approach to dose intensity.
Methods A retrospective analysis of data from MRC BO06/EORTC 80931 randomised controlled trial for treatment of 
osteosarcoma was conducted. Three types of post hoc patient groups are formed using the intended regimen: the individu-
ally achieved cumulative dose and time on treatment, and the increase of individual cumulative dose over time. Event-free 
survival is investigated and compared in these three stratifications.
Results The strata of intended regimen and achieved treatment yields equivalent results. Received cumulative dose over 
time produces groups with evident different survivorship characteristics. In particular, it highlights a group of patients with 
an estimated 3-year event-free survival much larger (more than 10%) than other patient groups. This group mostly contains 
patients randomised to an intensified regimen. In addition, adverse events reported by that group show the presence of 
increased preoperative myelotoxicity.
Conclusions The manuscript shows the benefits of analyzing studies by using longitudinal data, e.g. recorded per cycle. This 
has impact on the drafting of future trials by showing why such a level of detail is needed for both treatment and adverse 
event data. The novel method proposed, based on cumulative dose received over time, shows that longitudinal treatment data 
might be used to link survival outcome with drug metabolism. This is particularly valuable when pharmacogenetics data for 
metabolism of cytotoxic agents are not collected.
Trial registration ISRCTN86294690.
Keywords Bone tumour · Sarcoma · Chemotherapy · Personalised medicine
Abbreviations
RDI  Received dose intensity
tRDI  Target RDI
aRDI  Achieved RDI
rRDI  Regulated RDI
EFS  Event-free survival
Introduction
Received dose intensity (RDI) was first described by Hry-
niuk as the given dose (in mg/m2) during a certain time 
period [1]. This definition applies to either single cytostatic 
agents or drug combinations [2]. The prognostic value of 
high RDI in cancer survivorship has been discussed in 
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several studies [3–8] and for many cancer types; however, 
this debate has never reached consensus [9, 10].
In osteosarcoma, RDI increase can be achieved by sched-
ule compression supported by granulocyte colony-stimulat-
ing factor, e.g. by comparing 3-weekly doxorubicin plus 
cisplatin with a 2-weekly administration of the same agents 
at the same dosage [11]. This led to a 31% RDI increase and 
a significantly higher proportion of good histologic response 
in the intensified arm compared to the uncompressed control 
arm. Yet unexpectedly, an increase of RDI was not associ-
ated with a better survival, leading to the conclusion that his-
tologic response was not a good surrogate marker tout court 
for survival outcome in osteosarcoma, because its prognostic 
value is limited to homogeneous groups of patients.
Nevertheless, treatment decisions have been often based 
on histologic response [12]. However, the recently closed 
EURAMOS-1 study showed no evidence that regimen inten-
sification yields better survival outcome for poor histologic 
response [13]. Other studies have not shown a clear survival 
benefit when increasing dose intensity in osteosarcoma [14], 
perhaps indicating that the effect of treatment intensification 
should not be addressed by cohort comparison.
Treatment-induced toxicity has been shown to vary 
among different groups of age and gender [15]. Recently, it 
has been shown that variant expression of genes, involved in 
the metabolism of methotrexate, cisplatin and doxorubicin 
is related to progression-free survival in osteosarcoma [16, 
17]. This finding suggests the presence of inter-patient het-
erogeneity for metabolism of cytotoxic agents. Finally, there 
is evidence that lymphopenia is an independent prognostic 
factor for overall and progression-free survival in several 
cancers [18].
Besides pharmacogenetics, there are a number of other 
factors driving differences in RDI, many of which vary at 
the patient level. The aim of this study is to gain insight into 
the treatment effects in osteosarcoma. Thus, we analyse the 
difference in outcome results that is observed by using a pro-
gressively more individualised approach to dose intensity.
Patients and methods
Patients
Data for this study were collected from the MRC BO06/
EORTC 80931 (ISRCTN86294690) randomised con-
trolled trial for patients with newly diagnosed, resectable 
high-grade osteosarcoma. The trial compared pathological 
response and survival outcome of the control regimen (Reg-
C), six courses of 3-weekly doxorubicin (DOX, 75 mg/m2) 
and cisplatin (CDDP, 100 mg/m2), versus a dose-intense 
regimen (Reg-DI), same courses administered 2-weekly 
and supported by the hematopoietic growth factor G-CSF. 
Chemotherapy was given perioperatively. Surgical resection 
of primary osteosarcoma was scheduled at week 6 since the 
start of treatment, i.e. after 2 × DOX + CDDP for Reg-C and 
after 3 × DOX + CDDP for Reg-DI. Postoperative chemo-
therapy was intended to resume 3 weeks after surgery in 
both arms. The dataset consists of 497 consenting patients, 
prospectively enrolled between 1993 and 2002. More details 
about MRC BO06 can be found in the primary analysis of 
the trial [11].
Sample selection
From the original sample, we excluded 19 patients who did 
not start chemotherapy (13) or reported an abnormal dos-
age of one or both agents (6, given dose > 1.25 × prescribed 
dose). The outcome of interest is event-free survival (EFS), 
defined as time from the end of therapy until the occurrence 
of the first event defined as: local recurrence, evidence of 
new or progressive metastatic disease, second malignancy, 
death, or a combination of these events. We set a landmark at 
180 days since registration, since nearly all patients enrolled 
in MRC BO06 completed the allocated regimen. For the 
analysis, we further excluded 57 patients, who reported an 
event within day 180 since randomization (50) or had not 
completed therapy by day 180 since randomization (7).
Calculating target, achieved and regulated RDI
Both target RDI (tRDI) and achieved RDI (aRDI) are 
obtained from the standardised cumulative dose δ and the 
standardised time on treatment τ. The quantities δ and τ are 
computed on the prescribed regimen for tRDI, and on indi-
vidual patients’ treatment data for aRDI [19].
Regulated RDI (rRDI) extends the concept of aRDI by 
considering the longitudinal component: it is the evolution 
of the standardised cumulative dose δ over time. The new 
measure rRDI is a collection of values (δ, τ): each of these 
pairs corresponds to the cumulative dose and the cumu-
lative time on treatment at the end of a completed cycle. 
More details about the computation of rRDI can be found 
in “Appendix 1”.
Displaying of treatment data in the time–dose 
plane
Graphical techniques are used to visualise cumulative 
dose and treatment duration. We represent aRDI in the 
time–dose plane (τδ-plane), where the standardised time on 
treatment, τ, is on the x-axis and the standardised cumu-
lative dose received, δ, on the y-axis. In the τδ-plane, we 
represent patients’ aRDI with points, while rRDI is repre-
sented by lines made of linear pieces. Each piece in the line 
953Cancer Chemotherapy and Pharmacology (2019) 83:951–962 
1 3
corresponds to a cycle, where the slope represents the treat-
ment intensity achieved in that period.
Statistical methods
We formed strata of patients according to tRDI, aRDI, and 
rRDI, and estimated EFS by applying Kaplan–Meier meth-
odology on each stratification. We performed a landmark 
analysis at 180 days since randomization to investigate the 
association between RDI and EFS in the following scenar-
ios: (i) patients are divided on the allocated regimen ( C 
or Reg-DI) which leads to two strata of identical tRDI 
(tRDI-C, , tRDI-DI); (ii) patients are divided into four strata 
based on similarity of aRDI ( aRDI-0,  aRDI-1,  aRDI-2, 
 aRDI-3); (iii) patients are divided into four strata based on 
similarity of rRDI ( rRDI-0,  rRDI-1, rRDI-2, rRDI-3).
For scenarios (ii) and (iii), we formed post hoc patient 
groups (strata) by applying k-means clustering (unsuper-
vised machine learning) of aRDI and rRDI separately. The 
choice of defining four strata was motivated in previous 
research on aRDI [19]. The k-means clustering methodology 
provides homogeneous strata with respect to aRDI or rRDI. 
Patients who reported a similar cumulative dose in a simi-
lar time window (aRDI) are grouped together; patients who 
reported a similar course of treatment (rRDI) are grouped 
together. Details are provided in “Appendix 2”. For both 
aRDI and rRDI stratification, we also look at the distribution 
of tRDI across the strata and provide median values of τ, δ, 
and number of cycles.
All analyses are performed using Python 3.6.2 with pan-
das 0.20.2 [20], scikit-learn [21], and lifelines [22].
Results
Figure 1 shows patients in the τδ-plane and the interrela-
tionships between tRDI, aRDI, and rRDI. Figure 1a dis-
plays individual cumulative dose over time, i.e. rRDI lines, 
and compares them with those belonging to patients who 
reported no delays or reductions represented with the two 
thick black lines. Each line is obtained by joining the points 
(τ, δ) corresponding to each cycle. In Fig. 1b, aRDI and tRDI 
can be compared with patients who reported no delays or 
reductions, represented in the figure as black square (Reg-C 
target) and dot (Reg-DI target). Figure 1c shows that rRDI 
extends aRDI over time, because the pattern of the final 
rRDI-value is identical to that of Fig. 1b.
Each rRDI line presents a sharp change in the steepness in 
the central part of Fig. 1 top and bottom right: this marks the 
last preoperative cycle whose duration includes the surgery 
window. rRDI lines form a tight bundle in the early phase 
of the treatment, but later they open up in a hand-fan shape 
because treatment adjustments are generally more frequent 
towards the end of the protocol.
Figure 2 shows the stratification based on aRDI; each col-
our represents a different post hoc strata. Strata are obtained 
at the landmark point—i.e. not at randomisation—by clus-
tering patients with similar aRDI. Figure 3 shows rRDI-
based stratification and individual rRDI lines for each group. 
Median values of relevant clinical quantities are reported in 
Table 1 for each group.
The groups obtained by clustering of aRDI/rRDI can be 
interpreted as follows.
aRDI strata (different colours correspond 
to different strata)
Stratum  aRDI-0 is made of 34 patients of which 14 ran-
domised to Reg-C (41%) and 20 to Reg-DI (59%). These are 
mostly patients who prematurely terminated the allocated 
protocol as the median cumulative dose received (δ) was 
47% of the target one, while the median number of cycles 
completed is equal to 3.
Strata  aRDI-1 is made of 140 patients, of which 105 
were randomised to Reg-C (75%) and 35 to Reg-DI (25%). 
The median cumulative dose received was 99% of the antici-
pated one, with a median of six cycles completed, and the 
median duration of the treatment was 1.56 × 91 = 142 days. 
This is interpreted as the subgroup of Reg-C patients who 
had expected complications during their course of treatment, 
anticipated in the clinical trial protocol, and it also contains 
patients of the Reg-DI group who reported unexpected com-
plications and required strong treatment adaptations (cf. 
Figs. 1b, 2).
Stratum  aRDI-2 is made of 210 patients, of which 39 
were randomised to Reg-C (23%) and 130 to Reg-DI (77%). 
The median cumulative dose is 100% of the target one, and 
the median duration of their allocated treatment was 
1.26 × 91 = 115 days. Patients of the DI-group in this stratum 
completed their allocated treatment whilst reporting 
expected adaptations, while patients of the C-group com-
pleted their allocated treatment following quite closely the 
anticipated schedule. It can be interpreted as the subgroup 
of patients randomised to Reg-DI who had a course of treat-
ment with expected complications, but it also contains 
patients allocated to Reg-C who reported little to no 
complications.
Stratum  aRDI-3 is made of 78 patients with 44 ran-
domised to Reg-C (56%) and 34 to Reg-DI (44%). The 
median cumulative dose is 76% of the anticipated one, the 
median number of completed cycles is six, and the median 
duration of the treatment is 1.37 × 91 = 125 days. As the 
cumulative dose in this group is always larger than 50% and 
the treatment duration is generally larger than 1 × 91 = 91 
days (cf. Fig. 2), we conclude that this group is formed by a 
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mixture of patients who terminated the allocated treatment 
in the postoperative phase or completed it reporting major 
reductions.
rRDI strata (different colours correspond to different 
strata)
Stratum  rRDI-0 is made of 147 patients, of which 135 were 
randomised to Reg-C (92%) and 12 to Reg-DI (8%). The 
median cumulative dose is 97% of the target one, and the 
median duration of their allocated treatment was 
1.48 × 91 = 135 days. This group contains 67% of all 
C-patients.
Stratum  rRDI-1 is composed of 63 patients, of which 34 
were randomised to Reg-C (54%) and 29 to Reg-DI (46%). 
The median cumulative dose was 58% of the target one, the 
median number of cycles complete was four, and the median 
time on treatment was 0.78 × 91 = 71 days. These are patients 
who discontinued the protocol or experienced some compli-
cations during the course of treatment.
Strata rRDI-2 is made of 92 patients randomised to Reg-
DI, which accounts for 42% of all patients randomised to this 
regimen; it does not contain patients from the C-group. The 
median cumulative dose was 100% of the target one, and the 
median duration of their allocated treatment was 
1.19 × 91 = 108 days.
Fig. 1  a Individual standardised dose over time coloured by the allo-
cated regimen (pink: Reg-DI; purple: Reg-C); each line is a graphical 
representation of the regulated RDI (rRDI) of a patient; black lines 
show the anticipated (target) rRDI line of a patient randomised to 
Reg-DI (dotted) or Reg-C (solid); divergence of coloured lines from 
the target black one illustrates how complicated an individual course 
of treatment was. b Individual cumulative standardised dose vs stand-
ardised treatment duration; each point is a graphical representation 
of the achieved RDI of a patient (pink circle: Reg-DI; purple square: 
Reg-C); two thick black markers represent two fictitious patients who 
completed the protocol with no delays or dose reductions (dot: Reg-
DI; square: Reg-C). These black markers are a graphical representa-
tion of target RDI. The larger the distance of a coloured point from 
the corresponding black one, the more complicated the individual 
course of treatment. With respect to a, this view does not show where 
the complications were located in time. c As end points of rRDI lines 
match the pattern of achieved RDI visualised in b, regulated RDI cor-
rectly extends achieved RDI over time
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It is interesting to compare this group to rRDI-3: 129 
patients, of which 33 were from the C-group (28%) and 
86 from the DI-group (72%). The median cumulative dose 
was 94% of the target one, and the median duration of the 
protocol 1.40 × 91 = 127 days; rRDI-3 contains 39% of all 
DI-patients enrolled to the trial. Figure 3 shows that, com-
pared to rRDI-2, the rRDI-3 group shows less steep rRDI 
lines, i.e. cycle-wise less intense treatments. Since most 
patients were randomised to the same regimen (Reg-DI), 
the treatment-intensity reduction is due to a higher rate 
of toxicity-induced treatment adaptations in rRDI-3; see 
next section. Figure  3 also suggests that differences 
between rRDI-2 and rRDI-3 might be more evident in the 
preoperative phase.
Adverse events in rRDI strata
Figure 4 shows the proportion of patients in each rRDI stra-
tum (relative to the group size) who required adaptations 
(either delays or dose reductions) according to the case 
report form. Each panel shows across cycles how many 
patients required treatment adaptations and the correspond-
ing reason according to the case report form; cycles discon-
tinued do not contribute to the plot. Groups  rRDI-0 and 
rRDI-2 (especially the latter) are driven by late myelotoxic-
ity, but groups  rRDI-1 and rRDI-3 by early myelotoxicity. 
In addition,  rRDI-1 seems to be driven by ‘other’ reasons 
(most likely doxorubicin-induced cardiotoxicity, for which 
a dedicated checkbox was not present on the trial’s case 
Fig. 2  Individual cumulative standardised dose versus standardised treatment duration; patients are coloured in four groups determined by simi-
larity of achieved RDI; patients are marked according to their target RDI value (circle: patient randomised to Reg-DI; square: Reg-C)
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report form); rRDI-3 reports the highest proportion of 
adjustment due to myelotoxicity in the preoperative period.
Survival in strata of tRDI, aRDI, and rRDI
Figure 5 shows KM estimation of EFS obtained by stratify-
ing patients according to tRDI (Fig. 5a-1, a-2), aRDI (Fig. 5b-
1, b-2), or rRDI (Fig. 5c-1, c-2). For each estimated survival 
Fig. 3  Grouping of patients by similarity of regulated RDI and indi-
vidual rRDI lines of each group; each line shows the growth of the 
standardised cumulative dose received over time.  rRDI-0 is mostly 
composed of patients randomised to Reg-C (92%),  rRDI-1 cap-
tures treatment discontinuations and is balanced regimen-wise; 
rRDI-2 is composed only of patients allocated to Reg-DI; rRDI-3 
is composed for the large majority (72%) by patients randomised to 
Reg-DI. rRDI-2 shows steeper lines than any other group, which 
means that patients therein reported the highest received dose inten-
sity. In particular, rRDI-2 presents a marked difference with 
rRDI-3 in terms of line steepness that is more evident in the preop-
erative part of the regimen
Table 1  Characteristics of strata obtained by clustering patients on similar aRDI and rRDI
N pts N. Reg-C (%) N. Reg-DI (%) δ τ N. cycles
aRDI-0 34 14 (41%) 20 (59%) 0.47 0.39 3
aRDI-1 140 105 (75%) 35 (25%) 0.99 1.56 6
aRDI-2 210 39 (23%) 130 (77%) 1.00 1.26 6
aRDI-3 76 44 (56%) 34 (44%) 0.76 1.37 6
rRDI-0 147 135 (92%) 12 (8%) 0.97 1.48 6
rRDI-1 63 34 (54%) 29 (46%) 0.58 0.78 4
rRDI-2 92 0 (0%) 92 (100%) 1.00 1.19 6
rRDI-3 129 33 (28%) 86 (72%) 0.94 1.40 6
For each stratum, the table shows the total number of patients, percentage with respect to the allocated regimen, median values of standardised 
cumulative dose (δ), standardised cumulative time on treatment (τ), and number of cycles completed
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curve, the corresponding patient stratification is shown on the 
left panel.
EFS for strata based on tRDI (Fig. 5a-2) are similar to the 
survival based on strata of aRDI (Fig. 5b-2). KM curves for 
tRDI-C,  and tRDI-DI (Fig. 5a-2) are very similar to those of 
 aRDI-1 and  aRDI-2 (Fig. 5a-2), respectively. This is to be 
expected as these strata largely overlap pairwise.
However, stratifying patients according to rRDI (Fig. 5c) 
offers a very different picture. Patients in the group  rRDI-1 
show an EFS very similar to patients from the  aRDI-0 group 
(Fig. 5c-2). Strata  rRDI-0 and rRDI-2 show largely overlap-
ping survival curves, with 3-year EFS smaller than 50%. On 
the contrary, rRDI-3 (who had treatment-intensity reduction 
due to a high toxicity) shows better prognosis compared to 
strata  rRDI-0 and rRDI-2, with 3-year EFS larger than 60%. 
Strata are based only on individual treatment data; thus, the 
method is unaware of the efficacy outcome.
Conclusions
We presented a novel method to address the association 
between received dose intensity (RDI) and survival outcome 
by considering the treatment-intensity pattern achieved 
by each patient. This approach offers new insight into the 
direction of personalised treatment, extending beyond 
osteosarcoma.
We investigated event-free survival in patient groups 
that are homogeneous with respect to RDI at a progres-
sively more individualised level. This showed the benefits 
of investigating the association between RDI and survival at 
the patient level rather than at the usual cohort level.
The application of the method was shown using data 
from MRC BO06, a randomised clinical trial in osteosar-
coma. This is an interesting dataset because many studies 
in osteosarcoma have challenged the benefits of escalating 
the dosage and/or compressing the regimen cohort-wide, 
showing complex interrelationships between increased RDI, 
histologic response, and outcome [23, 24].
In this manuscript, we offered a novel tool for tackling the 
problem at the patient level. While grouping patients accord-
ing to the target dose intensity overlooks inter-patient differ-
ences, clustering based on the achieved intensity levels at 
the end of treatment does not consider which treatment adap-
tation patterns led to individual reductions and delays during 
the treatment. Conversely, grouping patients on similarity of 
received dosage patterns takes into account also the indi-
vidual tolerability to the regimen. As a result, we highlighted 
Fig. 4  Proportion of patient cycles that required adaptations (either 
delays or dose reductions) according to the study protocol and cor-
responding cause of adaptation as reported by the case report form. 
The view is per rRDI-group, i.e. per group of patients with similar 
regulated RDI pattern. The x-axis displays cycle number, while the 
y-axis shows the proportion of patients in the group who required 
adaptations. Groups  rRDI-0 and rRDI-2 are driven by late mye-
lotoxicity, while groups  rRDI-1 and rRDI-3 are driven by early 
myelotoxicity. In addition,  rRDI-1 seems to be driven by ‘other’ 
reasons (most likely doxorubicin-induced cardiotoxicity, for which a 
dedicated checkbox was not present on the trial’s case report form), 
and rRDI-3 reports the highest proportion of adjustment due to 
myelotoxicity in the preoperative period. Cycles discontinued do not 
contribute to the plot
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two subgroups of patients randomised to the dose-intense 
regimen who present quite different survival curves (rRDI-2 
and rRDI-3). Remarkably, the subgroup with the worst sur-
vival (rRDI-2, only patients from the DI-group and highest 
reported RDI) showed a KM curve that is nearly identical to 
the survival of the majority of patients from the C-group 
( rRDI-0). This finding seems to be linked to the individual 
tolerability because rRDI-2 and rRDI-3 (both mostly 
formed by patients of the DI-group) present differences in 
the individual treatment intensity reported, especially in the 
preoperative cycles (Fig. 3). A comparison with Fig. 7 from 
[14] suggests that the potential implications of this fact 
might be osteosarcoma specific.
We have also shown that longitudinal treatment data 
contain information about the link between adverse events 
and survival outcome (cf. Figs. 4, 5c). As such, longitudi-
nal treatment data might be used to link survival with drug 
metabolism when pharmacogenetics data are unavailable, 
like for MRC BO06. This link has been already investigated 
in small cell lung cancer through average binding occupan-
cies [25], a measure of which is a well-known predictor of 
both outcome and skin disorders. Studies in metastatic colo-
rectal cancer showed the effectiveness and safety of therapy 
schemes adapted on adverse events [26] or targeting toxicity-
related polymorphisms [27].
In conclusion, the strength of our method is the capability 
of detecting differences between patients randomised to the 
same regimen. Further, it seems to discriminate the prognos-
tic value of chemotherapy-related complications over time. 
Indeed, rRDI-3 appears to be the subgroup of patients ran-
domised to Reg-DI with the least tolerance to the regimen. 
In this respect, the manuscript offers a very precise view on 
the association between adverse events and osteosarcoma 
survival, which has been investigated through most severe 
chemotherapy-induced toxicity grades [28].
The method proposed here cannot be used yet in a pro-
spective way. Yet, the results presented above suggest that 
there is room for gaining more insight into the effects of 
treatment intensification if longitudinal data and proper 
connected methodologies are used. On the one hand, our 
study calls for developing new methodologies targeted at 
cancer types where the link between treatment and survival 
is complex or confused. On the other, it calls for the col-
lection of good-quality longitudinal data for both treatment 
and adverse events. Unfortunately, the level of detail avail-
able in the MRC BO06 dataset is not always accessible—an 
example is the recently concluded EURAMOS-1 trial. This 
in spite of treatment and adverse event data being longi-
tudinal and already recorded per cycle in medical records. 
Clearly, making large datasets available with good-quality, 
longitudinal trial data might easily become an important 
issue for the organisation of future trials with respect to 
coordination efforts/overheads. This manuscript demon-
strated that working in this direction might be a difficult, 
but rewarding approach.
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Appendix 1: Definition of tRDI, aRDI, 
and rRDI
Target received dose intensity (tRDI) is calculated as the 
ratio between standardised planned cumulative dose, δ, 
and standardised planned duration of regimen, τ. The 
former is obtained by standardising the sum of planned 
dose of all agents over all cycles of the allocated regi-
men; if a specific agent is not administered in a certain 
cycle, the contribution to the sum from that specific 
agent at that cycle is 0. Standardisation is performed by 
dividing the cumulative planned dose by the cumulative 
planned dose of a reference regimen. In MRC BO06, 
Fig. 5  Estimation of event-free survival in groups that are homoge-
neous with respect to RDI using a progressively more individualised 
definition of RDI. a-1 Groups defined with respect to target RDI and 
a-2 the corresponding Kaplan–Meier curves; b-1 groups defined with 
respect to achieved RDI and b-2 the corresponding survival curves; 
c-1 groups defined with respect to regulated RDI and c-2 the corre-
sponding survival curves
◂
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the cumulative planned dose is the same for each arm, 
6 × (100 + 75) = 1050 mg/m2, therefore standardisation 
with respect to Reg-DI yields δ = 100% for both Reg-C 
and Reg-DI. The standardised planned duration of a regi-
men is obtained by standardising the difference in days 
between the planned start of the last and the first cycle of 
the regimen. Standardisation is performed by dividing the 
cumulative planned dose by the cumulative planned dose 
of a reference regimen. In MRC BO06, Reg-DI and Reg-C 
have planned duration of 91 and 126 days, respectively. 
Standardising with respect to Reg-DI yields a value of 
τ = 91/126 = 72%. The final computations of tRDI are as 
follows: for Reg-C, 1050/1050 × 91/126 = 72%; for Reg-
DI, 1050/1050 × 91/91 = 100%.
Achieved received dose intensity (aRDI) is also calcu-
lated from standardised cumulative dose and standardised 
time-on-treatment, but these quantities are now computed 
on observed treatment data. For example, a patient report-
ing a 20% reduction in cycles 5 and 6 achieved a cumulative 
dose of 4 × (100 + 75) + 2 × (100 + 75) × 0.8 = 980 mg/m2, so 
δ = 980/1050 = 93%. In case an agent is omitted, the received 
dose of that agent in the formula is 0 for all the cycles 
affected by the omission; the same applies for all agents in 
case of discontinued cycles. Similarly, a patient who com-
pleted the protocol reporting a cumulative delay of 2 weeks 
(e.g. one 2-week delay or two 1-week delays at the begin-
ning of two distinct cycles) would have τ = 105/91 = 115% 
if allocated to Reg-DI, or τ = 133/84 = 153% if allocated to 
Reg-C. In general, two patients—even two Reg-C or two 
Reg-DI—will report different values of τ and δ depending 
on the individual realisation of their intended treatment, 
i.e. depending on the delays and dose reductions reported 
throughout the treatment. In the graphical representation, 
the ratio δ/τ is the slope of a line connecting the patient 
point with the origin (0, 0) of the τδ-plane. For patients who 
completed all planned cycles, the quantity δ/τ is close to the 
aRDI as defined in [14]. For patients who did not complete 
all planned cycles, the ratio δ/τ might be difficult to use in 
practice. A solution is either to work with the pair (δ, τ) or to 
multiply δ/τ by the proportion of cycles completed.
Regulated received dose intensity (rRDI) is the evolu-
tion of the standardised cumulative dose over time; rRDI 
is a function of the time on treatment: for each time t, rRDI 
is the aRDI that patients would report in case of protocol 
discontinuation at exactly that moment. Both regimens of 
MRC BO06 were composed of six cycles, where both agents 
were administered at the beginning of each cycle. Thus, the 
standardised cumulative dose will increase at most six times 
during the administration of the regimen (it will increase 
less times only in case of discontinuation). This means that 
for MRC BO06, rRDI can be represented as a sequence of 
(at most) six values, i.e. the sequence of aRDI values that 
patients would report if they discontinued after each cycle 
was administered.
For a fictitious DI-patient, who completed the protocol 
without delays or dose reductions, rRDI can be displayed 
as the sequence of (δ, τ)-values [(0.167, 0/91), (0.333, 
14/91), (0.500, 28/91), (0.667, 63/91), (0.833, 77/91), 
(1.000, 91/91)]; for the corresponding C-patient, [(0.167, 
0/91), (0.333, 21/91), (0.500, 63/91), (0.667, 84/91), (0.833, 
105/91), (1.000, 126/91)].
Appendix 2: Clustering of patients based 
on achieved and regulated received dose 
intensity (aRDI and rRDI)
Clustering forms groups of patients such that members of 
the same group are similar with respect to received dose 
intensity.
Clustering based on achieved received dose intensity 
(aRDI) is performed by grouping patients with similar val-
ues of δ and τ. In other words, clustering returns groups of 
patients who were administered a similar cumulative dose in 
a similar time window. This means that patients assigned to 
the same cluster will report similar aRDI, or closer to aRDI 
of an average patient in the same group than to aRDI of 
average patient from other groups. In particular, this kind of 
clustering will not separate well Reg-DI and Reg-C patients. 
Instead, it will group Reg-DI patients with large cumulative 
delays (due to a problematic course of therapy) with Reg-C 
with a regular course of therapy; it will also tend to group 
Reg-DI patients with a regular course of therapy with Reg-C 
patients who reported less than average or no delays at all.
Clustering based on regulated received dose intensity 
(rRDI) is performed by grouping patients with a similar course 
of therapy. Groups are formed using the relative increase of 
the cumulative dose over time. As explained in “Appendix 1”, 
rRDI can be represented as a sequence of (δ, τ)-values, one 
pair for each cycle administered. In case of MRC BO06, there 
can be up to 6 (δ, τ)-pairs. In other words, rRDI of a MRC 
BO06 patients can be described by the sequence [(δ1, τ1), (δ2, 
τ2), …, (δ6, τ6)], where δi and τi are the standardised cumula-
tive dose and time on treatment up to at the beginning of the 
ith cycle. The slopes are obtained as ρi = (δi+1 − δi)/(τi+1 − τi), 
i = 1, 2, …, 5. The slopes measure the intensity of the treat-
ment between the ith and the (i + 1)th cycle: if no reduction 
was applied to the nominal dosage of cycle i + 1, the increase 
(δi+1 − δi) equals 1/6 for both a Reg-DI and a Reg-C patient; if 
the start of cycle i + 1 was not delayed, the increase (τi+1 − τi) 
equals 14/84 for a Reg-DI patient and 21/84 for a Reg-C 
patient. As a consequence, ρi equals, respectively, 1 or 2/3 
for a Reg-DI and a Reg-C patient who did not report delays 
or dose reductions in cycle i + 1. If a delay or a reduction is 
applied, then ρi is smaller. In case a patient completes less 
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cycles than anticipated, some ρi cannot be calculated and are 
replaced by 0. Clustering is performed by grouping patients 
based on the similarity of the whole sequence of values [ρ1, 
ρ2, ρ3, ρ4, ρ5]. With this method, groups tend to separate bet-
ter Reg-C and Reg-DI patients, because information on the 
intended treatment (duration of cycles) is embedded in ρi at 
the cycle level and not just regimen-wise. Moreover, ρi carries 
information about the medical interventions that occurred in 
each cycle, offering a surrogate measure of individual toler-
ability to the allocated regimen.
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